June 17, 2020
During the 25th Congress of the European Hematology Association (EHA), KnowAML spoke to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE. The term 'AML' covers many different disease states, and individual cases are characterized by genetic aberrations, which cause the transition from normal cells to cancer cells. Efforts have been made to better understand these differences. As a result, treatments are now more personalized to individual patients, and improved patient outcomes have been observed.